HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Alejandro Aris Rafael Llorens Jaime Casares Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aris, A. Articles by Casares, J. Search for Related Content PubMed PubMed Citation Articles by Aris, A. Articles by Casares, J.

Ann Thorac Surg 1996;62:40-47
© 1996 The Society of Thoracic Surgeons

---

Original Articles: Cardiovascular

The Spanish Monostrut Study Group: A Ten-Year Experience With 8,599 Implants

Cardiac Surgery Centers in Barcelona, Madrid, Santander, Pamplona, and Córdoba, Spain

Background. The Monostrut valve is a pyrolytic carbon, tilting-disc prosthesis with no welds. After the first implantation in Spain in May 1983, the Spanish Monostrut Study Group was established to evaluate prospectively the performance of the valve using uniform protocols.

Methods. During a 10-year period, 8,599 Monostrut valves were implanted in 7,317 patients in 22 centers. Mean age was 53.3 ± 11 years. Of the total group, 3,229 underwent aortic valve replacement, 2,806 had mitral valve replacement, and 1,282 had double valve replacement. Follow-up was 96% complete, with a mean period of 4.3 years and a total of 29,155 patient-years.

Results. The operative mortality rate was 7.2%. The 10-year probability of freedom from valve-related complications and linearized rates (event/100 patient-years in parentheses) were as follows: structural deterioration, 100% (0); nonstructural dysfunction, 96% ± 0.5% (0.51); thromboembolism, 82.9% ± 1.5% (1.32); anticoagulant-related hemorrhage, 87.6% ± 1.4% (0.98); and prosthetic valve endocarditis, 96.1% ± 0.5% (0.48). There were five obstructive valve thromboses (0.017/100 patient-years). Actuarial freedom from reoperation was 95% ± 0.5% at 10 years. Actuarial freedom from all valve-related morbidity was 70.2% ± 1.6%; freedom from all valve-related morbidity and mortality (including operative and sudden deaths) was 62.6% ± 2% (70.1% ± 2% for aortic valve replacement, 56.9% ± 2% for mitral valve replacement, and 59.8% ± 3% for double valve replacement; p < 0.0001). Clinically, 5,988 patients (94%) are in New York Heart Association class I-II.

Conclusions. The Monostrut valve has shown no structural failures and a low rate of valve-related complications over a 10-year period in a large patient population.

This article has been cited by other articles:

				D. N. Salem, P. T. O'Gara, C. Madias, and S. G. Pauker Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 593S - 629S. [Abstract] [Full Text] [PDF]

				D. N. Salem, P. D. Stein, A. Al-Ahmad, H. I. Bussey, D. Horstkotte, N. Miller, and S. G. Pauker Antithrombotic Therapy in Valvular Heart Disease--Native and Prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 457S - 482S. [Abstract] [Full Text] [PDF]

				R. Vink, R. A. Kraaijenhagen, B. A. Hutten, R. B. A. van den Brink, B. A. de Mol, H. R. Buller, and M. Levi The optimal intensity of vitamin k antagonists in patients with mechanical heart valves: A meta-analysis J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2042 - 2048. [Abstract] [Full Text] [PDF]

				M. Murtra The adventure of cardiac surgery Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 167 - 180. [Full Text] [PDF]

				P. D. Stein, J. S. Alpert, H. I. Bussey, J. E. Dalen, and A. G.G. Turpie Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves Chest, January 1, 2001; 119 (2009): 220S - 227S. [Full Text] [PDF]

				S. Torregrosa, J. Gomez-Plana, F. J. Valera, J. Caffarena, J. M. Maronas, F. Garcia-Sanchez, J. Peris, R. Frias, and J. M. Caffarena Long-term clinical experience with the omnicarbon prosthetic valve Ann. Thorac. Surg., September 1, 1999; 68(3): 881 - 886. [Abstract] [Full Text] [PDF]

				A. Aris and J. M. Gil Jaurena Leaflet preservation in mitral valve replacement with a tilting-disc valve Ann. Thorac. Surg., January 1, 1999; 67(1): 293 - 294. [Full Text] [PDF]

				C. E.E. Kuntze, E. H. Blackstone, and T. Ebels Thromboembolism and mechanical heart valves: a randomized study revisited Ann. Thorac. Surg., July 1, 1998; 66(1): 101 - 107. [Abstract] [Full Text] [PDF]